India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
The company announced positive topline data from the Phase 3 ADorable-1 trial
One task, one interaction, one pair, experts advocate
The conflict is also triggering a widening public health emergency
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Pivya is Alembic’s first branded pharmaceutica product in the US and is being marketed through Alembic Therapeutics LLC
Our clinical data suggests ProLectin-M demonstrated earlier reductions in viral shedding compared with placebo with a favorable safety profile
Ivermectin Tablets USP, 3 mg, are prescription anti-parasitic medications primarily indicated for treating parasitic worm infections in humans
Subscribe To Our Newsletter & Stay Updated
